HRS4R
Vull donar

DAVID GALLARDO GIRALT

Firma
DAVID GALLARDO-GIRALT
Posició
Cap de Grup - R4
Caps de Grup - R4

Projectes

Codi oficial: PI20/01353 Data inici: 01/01/2021 Data fi: 31/12/2023 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 135,520 €

Publicacions

Bataller A, Garrido A, Guijarro F, Oñate G, Diaz-Beya M, Arnan M, Tormo M, Vives S, Queipo DE Llano MP, Coll R, Gallardo D, Vall-Llovera F, Escoda L, García-Guiñon A, Salamero O, Sampol A, Merchan B, Bargay J, Castaño-Díez S, Esteban D, Oliver-Caldes A, Rivero A, Mozas P, López-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

Blood Advances, 2022, 6, 1193-1206 dx.doi.org/10.1182/bloodadvances.2021005585
0

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.

ANNALS OF HEMATOLOGY, 2022, 101, 1567-1576 dx.doi.org/10.1007/s00277-022-04841-8

Acha P, Hoyos M, Pratcorona M, Fuster-Tormo F, Palomo L, Ortega E, Zamora L, Vives S, Granada I, Montoro J, Garcia A, Arnan M, Cervera M, Canet M, Gallardo D, Arenillas L, Esteve J, Baragay J, Salamero O, Motlló C, Ortín X, Sierra J, Solé F

Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.

LEUKEMIA RESEARCH, 2021, 101, 106492-106492 dx.doi.org/10.1016/j.leukres.2020.106492

Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D, on the behalf of CETLAM Group

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.

Leukemia, 2020, 34, 2925-2933 dx.doi.org/10.1038/s41375-020-0784-2

Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Volin L, Salmenniemi U, Putkonen M, Buño I, Gallardo D, Itälä-Remes M, Partanen J, Ritari J

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Frontiers in Immunology, 2020, 11, 19-19 dx.doi.org/10.3389/fimmu.2020.00019

Parody R, Sánchez-Ortega I, Ferrá C, Guardia R, Talarn C, Encuentra M, Fort E, López D, Morgades M, Alonso E, Ortega S, Sarrá J, Gallardo D, Ribera JM, Sureda A

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.

Oncology And Therapy, 2020, 8, 311-324 dx.doi.org/10.1007/s40487-020-00115-3

Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S, PETHEMA, CETLAM cooperative groups

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.

EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105, 138-147 dx.doi.org/10.1111/ejh.13417

Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M

Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain.

CANCER CAUSES & CONTROL, 2018, 29, 379-382 dx.doi.org/10.1007/s10552-018-1004-5

Santos N, Rodríguez-Romanos R, de la Cámara R, Brunet S, Nieto JB, Buño I, Martínez C, Jiménez-Velasco A, Vallejo C, González M, Solano C, Ferrá C, Sampol A, Pérez-Simón JA, López-Jiménez J, Díez JL, Gallardo D

PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.

ANNALS OF HEMATOLOGY, 2018, 97, 2217-2224 dx.doi.org/10.1007/s00277-018-3438-y

Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Leukemia & lymphoma, 2018, 59, 2383-2393 dx.doi.org/10.1080/10428194.2017.1422858

Formulari de contacte

Coneix l’IDIBGI!

menu